Party at BIO conference that featured topless dancers draws fire from organization
One attendee called the PABNAB party entertainment "tone-deaf," but it's not the first event of its kind at a biotech show.
Gates Foundation debuts nonprofit biotech firm at BIO
The Gates Medical Research Institute will develop products for malaria, tuberculosis, enteric and diarrheal diseases.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
CAR-T has a lot of promise, but some big challenges remain, experts at BIO, ASCO say
Many issues around CAR-T remain to be hashed out, but many experts pointed to infrastructure and clinics' capabilities as crucial.
Janssen sees a potential myeloma CAR-T edge, exec says at BIO
The company plans to open its upcoming trial of a Chinese-developed CAR-T at four initial sites later this year.
Gottlieb at BIO: FDA developing processes around right-to-try law
FDA commissioner gives clues of agency's right-to-try strategy in Q&A session during chat with BIO President Jim Greenwood.
Experts at BIO, ASCO weigh in on CAR-Ts versus bispecific antibodies
CAR-Ts have generated excitement, but bispecific monoclonal antibodies may continue to have a competitive edge in some cases.
presented by
A Personalized Approach to Medication Nonadherence
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.